
    
      The duration of the study was 29 weeks at maximum. The screening and wash-out period lasted
      for up to 14 days, depending on the half-life of the medications followed by an 8-day
      baseline period including the treatment day. Overall, there were up to 21 days between
      signing informed consent (at screening visit) and the randomization (Day 1). Treatment was
      administered on Day 1, and follow-up period was 26 weeks.
    
  